{"schema_version":"secwatch.filing_event.v1","accession":"0000926617-26-000012","form_type":"8-K/A","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2026-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.069626+00:00","generated_at":"2026-05-15T09:09:03.716809+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Aspira enters lab services pact with Mayo Clinic for Ova1Plus and OvaWatch tests","bullets":["Agreement effective Dec 16, 2025; Mayo will list Aspira’s Ova1Plus and OvaWatch in its test catalog.","Mayo obligated to set minimum list prices (redacted); will market tests to its clients.","Initial term (redacted years) with automatic renewal; either party may terminate without cause on (redacted) days notice.","Testing is non-exclusive and on an as-requested basis; many financial terms remain confidential.","Partnership leverages Mayo’s national distribution to expand reach of Aspira’s ovarian cancer tests."],"urls":{"canonical":"https://secwatch.observer/filing/0000926617-26-000012","json":"https://secwatch.observer/filing/0000926617-26-000012.json","markdown":"https://secwatch.observer/filing/0000926617-26-000012.md","text":"https://secwatch.observer/filing/0000926617-26-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000092661726000012/0000926617-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000092661726000012/awhl-20251223x8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:09:03.716809+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"861763596b85975b9ef1312d72d6d70012b3964f","claim":"Aspira Women's Health Inc. entered into Laboratory Services Agreement with Mayo Collaborative Services, Inc. d/b/a Mayo Clinic Laboratories valued at Not disclosed (effective 2025-12-16).","evidence_excerpt":"On December 23, 2025, Aspira Women’s Health Inc. (“Aspira”) disclosed that we had entered into a Laboratory Services Agreement (the “Agreement”) with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories (“Mayo”), effective as of December 16, 2025.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000092661726000012/0000926617-26-000012-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Mayo Collaborative Services, Inc. d/b/a Mayo Clinic Laboratories"},{"label":"Value","value":"Not disclosed"},{"label":"Effective","value":"2025-12-16"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}